Compare
Lexaria Bioscience Corp. vs Polomar Health Services, Inc. vs Onconetix, Inc. vs Rallybio Corp
| Latest fiscal year | Lexaria Bioscience Corp. LEXX | Polomar Health Services, Inc. PMHS | Onconetix, Inc. ONCO | Rallybio Corp RLYB |
|---|---|---|---|---|
| Year ended | 2025-08-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $705.9K | $648.2K | $815.4K | $858.0K |
| Revenue growth (YoY) | +52.0% | n/m | -67.7% | +34.9% |
| Gross margin | 99.6% | 71.0% | 77.6% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$11.90M | -$10.70M | -$14.03M | -$8.98M |
| EPS (Diluted) | -$0.66 | -$0.39 | -$16.56 | -$1.59 |
| Operating cash flow | -$10.45M | -$396.0K | -$9.68M | -$29.81M |
| Free cash flow | -$10.48M | n/a | n/a | n/a |
| Cash & equivalents | n/a | $132.2K | n/a | $31.37M |
| Total assets | $4.18M | $390.0K | $24.93M | $62.26M |
| Total liabilities | $1.57M | $1.61M | $9.16M | $4.30M |
| Shareholders' equity | $2.99M | -$1.22M | $15.76M | $57.96M |
| Return on year-end equity | -398.1% | n/a | -89.0% | -15.5% |
| Shares outstanding | 19.56M | 28.02M | 1.56M | 5.28M |
Revenue, most recent five fiscal years
| Fiscal year | Lexaria Bioscience Corp. | Polomar Health Services, Inc. | Onconetix, Inc. | Rallybio Corp |
|---|---|---|---|---|
| Latest | $705.9K Ended 2025-08-31 | $648.2K Ended 2025-12-31 | $815.4K Ended 2025-12-31 | $858.0K Ended 2025-12-31 |
| 1 year earlier | $464.3K Ended 2024-08-31 | $58.8K Ended 2024-12-31 | $2.52M Ended 2024-12-31 | $636.0K Ended 2024-12-31 |
| 2 years earlier | $226.2K Ended 2023-08-31 | $41.8K Ended 2023-12-31 | $58.5K Ended 2023-12-31 | n/a |
| 3 years earlier | $255.4K Ended 2022-08-31 | $34.5K Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $722.7K Ended 2021-08-31 | n/a | n/a | n/a |